Market Summary
USD4.60+0.02
Delayedas of 20 Sep 2023, 02:28 pm0.44%
MGNX Stock Price
MGNX RSI Chart
MGNX Valuation
MGNX Price/Sales (Trailing)
MGNX Profitability
MGNX Fundamentals
MGNX Revenue
MGNX Earnings
Price Action
52 Week Range
2.937.90
(Low)(High)
Last 7 days
-7.3%
Last 30 days
-7.3%
Last 90 days
-19.8%
Trailing 12 Months
32.0%
MGNX Financial Health
MGNX Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for MGNX
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-09-07 | BIOTECH TARGET N V | bought | 1,052,840 | 5.2642 | 200,000 | - |
2023-08-30 | HURWITZ EDWARD | bought | 73,650 | 4.91 | 15,000 | - |
2023-03-10 | Peters Jeffrey Stuart | sold | -32,393 | 6.03 | -5,372 | senior vp and general counsel |
2023-02-22 | Peters Jeffrey Stuart | acquired | - | - | 8,750 | senior vp and general counsel |
2023-02-22 | Bonvini Ezio | acquired | - | - | 9,375 | sr vp, research & cso |
2023-02-22 | Bonvini Ezio | sold (taxes) | -23,704 | 6.55 | -3,619 | sr vp, research & cso |
2023-02-22 | Peters Jeffrey Stuart | sold (taxes) | -22,125 | 6.55 | -3,378 | senior vp and general counsel |
2023-02-14 | BIOTECH TARGET N V | bought | 2,532,600 | 5.0652 | 500,000 | - |
2023-01-19 | BIOTECH TARGET N V | bought | 794,925 | 5.2995 | 150,000 | - |
2022-12-27 | BIOTECH TARGET N V | bought | 1,121,800 | 5.609 | 200,000 | - |
Which funds bought or sold MGNX recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-08-21 | OSAIC HOLDINGS, INC. | reduced | -99.21 | -319,175 | 1,882 | -% |
2023-08-21 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -9.67 | -52,383 | 108,311 | -% |
2023-08-16 | Nuveen Asset Management, LLC | added | 36.99 | 109,045 | 5,010,040 | -% |
2023-08-15 | ALLIANCEBERNSTEIN L.P. | unchanged | - | -195,832 | 575,660 | -% |
2023-08-15 | CAXTON ASSOCIATES LP | reduced | -88.54 | -791,874 | 74,033 | 0.01% |
2023-08-15 | GOLDMAN SACHS GROUP INC | added | 20.29 | -243,346 | 2,132,760 | -% |
2023-08-15 | CAPTRUST FINANCIAL ADVISORS | new | - | 86,221 | 86,221 | -% |
2023-08-15 | ZACKS INVESTMENT MANAGEMENT | sold off | -100 | -94,658 | - | -% |
2023-08-15 | PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO | unchanged | - | -22,000 | 65,000 | -% |
2023-08-15 | WELLS FARGO & COMPANY/MN | added | 120 | 50,495 | 128,325 | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of MacroGenics
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 14, 2023 | armistice capital, llc | 9.91% | 6,092,000 | SC 13G | |
| Feb 14, 2023 | bb biotech ag | 14.5% | 8,929,963 | SC 13G/A | |
| Feb 14, 2023 | rtw investments, lp | 0% | 0 | SC 13G/A | |
| Feb 10, 2023 | wasatch advisors inc | - | 0 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 7.23% | 4,444,364 | SC 13G/A | |
| Feb 08, 2023 | goldman sachs group inc | 4.6% | 2,808,736 | SC 13G/A | |
| Jan 24, 2023 | blackrock inc. | 9.7% | 5,990,505 | SC 13G/A | |
| Jan 18, 2023 | millennium management llc | 4.6% | 2,807,235 | SC 13G/A | |
| Sep 02, 2022 | millennium management llc | 5.2% | 3,187,639 | SC 13G | |
| Aug 15, 2022 | ra capital management, l.p. | 0% | 0 | SC 13G/A |
Recent SEC filings of MacroGenics
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Sep 11, 2023 | 4 | Insider Trading | |
| Sep 01, 2023 | 4 | Insider Trading | |
| Aug 09, 2023 | 8-K | Current Report | |
| Aug 09, 2023 | 10-Q | Quarterly Report |
Peers (Alternatives to MacroGenics)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
BGNE | 287.4B | 1.8B | 8.19% | 34.91% | -165.92 | 158.74 | 69.45% | 14.65% |
ABBV | 271.2B | 56.0B | 2.23% | 8.69% | 31.23 | 4.84 | -2.31% | -31.27% |
VRTX | 92.4B | 9.5B | 3.90% | 25.64% | 27.45 | 9.72 | 13.83% | 5.33% |
REGN | 89.5B | 12.7B | 3.00% | 16.97% | 20.83 | 7.07 | -10.94% | -24.40% |
ALNY | 21.9B | 1.2B | -5.57% | -18.68% | -20.63 | 17.73 | 39.94% | -8.44% |
SRPT | 11.1B | 1.0B | 6.45% | 3.35% | -12.24 | 11.07 | 20.15% | -79.16% |
UTHR | 10.4B | 2.1B | -3.97% | 1.74% | 11.88 | 4.9 | 18.01% | 38.16% |
| MID-CAP | ||||||||
MDGL | 3.1B | - | -5.78% | 157.92% | -9.48 | - | - | -28.88% |
BPMC | 3.1B | 225.6M | 4.14% | -26.79% | -5.62 | 13.8 | -2.11% | 21.02% |
RARE | 2.6B | 402.9M | 3.70% | -20.53% | -3.61 | 6.46 | 20.50% | -42.46% |
MRTX | 1.9B | 27.2M | -16.17% | -58.23% | -2.56 | 69.33 | - | -14.43% |
| SMALL-CAP | ||||||||
CYTK | 3.1B | - | 1.51% | -37.05% | -7.31 | 33.28 | 34.30% | -149.91% |
CPRX | 1.4B | 302.9M | -11.98% | -2.00% | 11.71 | 4.47 | 77.72% | 112.02% |
MGNX | 283.7M | 152.5M | -7.29% | 31.99% | 38.08 | 1.86 | 127.84% | 103.41% |
CRBP | 30.6M | - | -1.14% | 3544.51% | -0.66 | - | - | -31.51% |
MacroGenics News
Returns for MGNX
Cumulative Returns on MGNX
-24%
7-Year Cumulative Returns
-27.4%
5-Year Cumulative Returns
-47.5%
3-Year Cumulative Returns
Risks for MGNX
What is the probability of a big loss on MGNX?
100%
Probability that MacroGenics stock will be more than 20% underwater in next one year
100%
Probability that MacroGenics stock will be more than 30% underwater in next one year.
85.8%
Probability that MacroGenics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does MGNX drawdown profile look like?
Y-axis is the maximum loss one would have experienced if MacroGenics was unfortunately bought at previous high price.
Drawdowns
Financials for MacroGenics
Income Statement (Last 12 Months)
| Income Statement (Last 12 Months) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Revenue | -7.8% | 152,465,000 | 165,336,000 | 151,941,000 | 92,989,000 | 66,917,000 | 71,667,000 | 77,447,000 | 115,991,000 | 118,582,000 | 108,082,000 | 104,883,000 | 77,384,000 | 77,872,000 | 68,208,000 | 64,188,000 | 54,790,000 | 56,847,000 | 65,088,000 | - | - | - |
| Costs and Expenses | -3.8% | 248,825,000 | 258,542,000 | 273,359,000 | 284,626,000 | 286,586,000 | 289,807,000 | 280,242,000 | 262,720,000 | 248,459,000 | 244,990,000 | 235,943,000 | 244,929,000 | 247,226,000 | 243,221,000 | 241,373,000 | 234,998,000 | 234,115,000 | 233,701,000 | 231,327,000 | 221,245,000 | 214,830,000 |
| S&GA Expenses | 0.0% | 56,246,000 | 56,223,000 | 58,949,000 | 60,860,000 | 62,666,000 | 64,231,000 | 63,014,000 | 59,992,000 | 52,563,000 | 47,545,000 | 42,742,000 | 42,071,000 | 44,172,000 | 46,078,000 | 46,064,000 | 44,721,000 | 42,472,000 | 41,484,000 | 40,500,000 | 38,357,000 | 37,176,000 |
| R&D Expenses | -4.4% | 182,945,000 | 191,460,000 | 207,026,000 | 217,226,000 | 218,858,000 | 222,894,000 | 214,577,000 | 201,024,000 | 195,857,000 | 197,428,000 | 193,201,000 | 202,858,000 | 203,054,000 | 197,143,000 | 195,309,000 | 190,277,000 | 191,643,000 | 192,217,000 | 190,827,000 | 182,888,000 | 177,654,000 |
| Interest Expenses | - | 3,096,000 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | 108.2% | 7,449,000 | -91,324,000 | -119,758,000 | -190,582,000 | -218,655,000 | -217,286,000 | -202,115,000 | -146,180,000 | -129,337,000 | -136,287,000 | -129,739,000 | -158,048,000 | -166,636,000 | -151,518,000 | -151,811,000 | -166,059,000 | -155,457,000 | -166,934,000 | -171,453,000 | -21,082,000 | -34,096,000 |
| Net Income Margin | 100.0% | - | -0.55 | -0.79 | -2.05 | -3.27 | -3.03 | -2.61 | -1.26 | -1.09 | -1.26 | -1.24 | -2.04 | -2.14 | -2.22 | -2.37 | - | - | - | - | - | - |
| Free Cashflow | 100.0% | - | -44,663,000 | -90,582,000 | -175,193,000 | -181,895,000 | -179,480,000 | -150,031,000 | -103,440,000 | -112,688,000 | -102,071,000 | -117,804,000 | -148,002,000 | -139,994,000 | -152,279,000 | -138,559,000 | - | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Assets | -11.0% | 306 | 343 | 280 | 195 | 218 | 271 | 335 | 392 | 426 | 435 | 379 | 374 | 328 | 265 | 313 | 351 | 384 | 415 | 332 | 355 | 387 |
| Current Assets | -11.9% | 255 | 289 | 222 | 148 | 168 | 218 | 280 | 335 | 367 | 375 | 313 | 310 | 260 | 195 | 240 | 276 | 288 | 335 | 269 | 286 | 322 |
| Cash Equivalents | -51.5% | 109 | 224 | 109 | 84.00 | 21.00 | 47.00 | 123 | 191 | 189 | 218 | 181 | 202 | 197 | 93.00 | 126 | 157 | 180 | 239 | 220 | 202 | 239 |
| Inventory | 2.4% | 1.00 | 1.00 | 1.00 | 1.00 | 3.00 | 5.00 | 4.00 | 4.00 | 6.00 | 6.00 | - | - | - | - | - | - | - | - | - | - | - |
| Net PPE | -10.1% | 24.00 | 27.00 | 30.00 | 32.00 | 34.00 | 36.00 | 38.00 | 39.00 | 39.00 | 40.00 | 42.00 | 41.00 | 44.00 | 46.00 | 48.00 | 50.00 | 52.00 | 55.00 | 57.00 | 59.00 | 57.00 |
| Liabilities | -42.7% | 134 | 234 | 138 | 72.00 | 76.00 | 93.00 | 96.00 | 101 | 107 | 85.00 | 83.00 | 83.00 | 80.00 | 75.00 | 82.00 | 96.00 | 89.00 | 94.00 | 89.00 | 73.00 | 75.00 |
| Current Liabilities | -1.0% | 45.00 | 46.00 | 49.00 | 50.00 | 51.00 | 67.00 | 75.00 | 69.00 | 70.00 | 53.00 | 51.00 | 50.00 | 46.00 | 40.00 | 45.00 | 58.00 | 50.00 | 52.00 | 60.00 | 48.00 | 48.00 |
| Shareholder's Equity | 57.0% | 172 | 109 | 142 | 123 | 142 | 178 | 240 | 291 | 319 | 351 | 296 | 292 | 248 | 191 | 231 | 255 | 294 | 321 | 243 | 283 | 312 |
| Retained Earnings | 5.1% | -1,074 | -1,131 | -1,093 | -1,106 | -1,081 | -1,040 | -973 | -915 | -863 | -823 | -771 | -769 | -733 | -686 | -642 | -611 | -567 | -535 | -490 | -445 | -411 |
| Additional Paid-In Capital | 0.4% | 1,245 | 1,240 | 1,235 | 1,229 | 1,224 | 1,218 | 1,213 | 1,207 | 1,181 | 1,173 | 1,067 | 1,061 | 981 | 877 | 872 | 866 | 861 | 855 | 733 | 728 | 723 |
| Shares Outstanding | 0.2% | 62.00 | 62.00 | 62.00 | 61.00 | 61.00 | 61.00 | 61.00 | 61.00 | 60.00 | 57.00 | 56.00 | 54.00 | 50.00 | 49.00 | 49.00 | 49.00 | 47.00 | 46.00 | 41.00 | 42.00 | 40.00 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Cashflow From Operations | 111.8% | 5.00 | -42.10 | -86.96 | -170 | -175 | -172 | -143 | -95.05 | -105 | -96.79 | -111 | -144 | -136 | -148 | -134 | -123 | -143 | -151 | -153 | -14.16 | -8.53 |
| Share Based Compensation | -4.5% | 19.00 | 20.00 | 20.00 | 21.00 | 22.00 | 23.00 | 23.00 | 23.00 | 22.00 | 21.00 | 21.00 | 21.00 | 20.00 | 20.00 | 20.00 | 18.00 | 18.00 | 17.00 | 17.00 | 16.00 | 15.00 |
| Cashflow From Investing | -116.4% | -19.22 | 117 | 71.00 | 63.00 | -11.61 | -20.83 | -36.61 | -39.13 | -79.79 | -52.61 | -7.78 | 16.00 | 53.00 | 2.00 | -79.36 | -41.91 | -35.54 | -33.23 | 57.00 | 20.00 | 25.00 |
| Cashflow From Financing | -0.2% | 102 | 102 | 2.00 | 1.00 | 20.00 | 22.00 | 123 | 123 | 178 | 275 | 174 | 174 | 100 | 1.00 | 120 | 120 | 120 | 223 | 105 | 105 | 106 |
MGNX Income Statement
2023-06-30CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
| Revenues: | ||||
| Revenues | $ 13,136 | $ 26,007 | $ 37,632 | $ 37,108 |
| Costs and expenses: | ||||
| Cost of product sales | 258 | 180 | 371 | 228 |
| Cost of manufacturing services | 919 | 2,222 | 4,329 | 2,222 |
| Research and development | 43,229 | 51,744 | 89,101 | 113,182 |
| Selling, general and administrative | 13,692 | 13,669 | 27,219 | 29,922 |
| Total costs and expenses | 58,098 | 67,815 | 121,020 | 145,554 |
| Loss from operations | (44,962) | (41,808) | (83,388) | (108,446) |
| Gain on modification of debt | 100,930 | 0 | 100,930 | 0 |
| Interest and other income | 2,275 | 504 | 3,348 | 699 |
| Interest expense | (774) | 0 | (1,430) | 0 |
| Net loss | 57,469 | (41,304) | 19,460 | (107,747) |
| Other comprehensive income (loss): | ||||
| Unrealized loss on investments | (80) | (43) | (67) | (265) |
| Comprehensive income (loss) | $ 57,389 | $ (41,347) | $ 19,393 | $ (108,012) |
| Net income (loss) per common share: | ||||
| Basic net loss per common share (in usd per share) | $ 0.93 | $ (0.67) | $ 0.31 | $ (1.76) |
| Diluted net loss per common share (in usd per share) | $ 0.92 | $ (0.67) | $ 0.31 | $ (1.76) |
| Weighted average common shares outstanding: | ||||
| Basic weighted average common shares outstanding (in shares) | 61,880,096 | 61,384,943 | 61,845,151 | 61,354,721 |
| Diluted weighted average common shares outstanding (in shares) | 62,261,646 | 61,384,943 | 62,030,710 | 61,354,721 |
| Collaborative and other agreements | ||||
| Revenues: | ||||
| Revenues | $ 6,021 | $ 16,863 | $ 22,708 | $ 23,956 |
| Product sales, net | ||||
| Revenues: | ||||
| Revenues | 5,062 | 4,672 | 8,552 | 8,252 |
| Government agreements | ||||
| Revenues: | ||||
| Revenues | 466 | 480 | 749 | 908 |
| Contract Manufacturing | ||||
| Revenues: | ||||
| Revenues | 1,587 | 3,992 | 5,202 | 3,992 |
| RevenueFromRoyalityAgreementsMember | ||||
| Revenues: | ||||
| Revenues | $ 0 | $ 0 | $ 421 | $ 0 |
MGNX Balance Sheet
2023-06-30CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 108,758 | $ 108,884 |
| Marketable securities | 131,589 | 45,462 |
| Accounts receivable | 6,410 | 56,222 |
| Inventory, net | 1,443 | 1,451 |
| Prepaid expenses and other current assets | 6,475 | 10,161 |
| Total current assets | 254,675 | 222,180 |
| Property, equipment and software, net | 24,091 | 29,575 |
| Right-of-use asset | 25,501 | 27,335 |
| Other non current assets | 1,386 | 1,378 |
| Total assets | 305,653 | 280,468 |
| Current liabilities: | ||
| Accounts payable | 3,795 | 4,899 |
| Accrued expenses and other current liabilities | 27,528 | 28,998 |
| Deferred revenue | 9,671 | 9,988 |
| Lease liabilities | 4,161 | 4,726 |
| Total current liabilities | 45,155 | 48,611 |
| Deferred revenue, net of current portion | 58,538 | 59,480 |
| Lease liabilities, net of current portion | 30,158 | 30,106 |
| Other non current liabilities | 258 | 258 |
| Total liabilities | 134,109 | 138,455 |
| Stockholders' equity: | ||
| Common stock, $0.01 par value -- 125,000,000 shares authorized, 61,938,493 and 61,701,467 shares outstanding at June 30, 2023 and December 31, 2022, respectively | 619 | 617 |
| Additional paid-in capital | 1,245,231 | 1,235,095 |
| Accumulated other comprehensive income (loss) | (72) | (5) |
| Accumulated deficit | (1,074,234) | (1,093,694) |
| Total stockholders' equity | 171,544 | 142,013 |
| Total liabilities and stockholders' equity | $ 305,653 | $ 280,468 |
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. It also develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.